Transformative Licensing Acquisition Drives Buy Rating for Monopar Therapeutics
Analyst Sean Lee CFA of H.C. Wainwright maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report), boosting the price ...
Monopar Therapeutics price target raised to $22 from $6 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $22 from $6 and keeps a Buy rating on the shares. The ...
Schroders' new CEO shakes up top team after bruising year
New Schroders CEO Richard Oldfield has more than halved the size of the asset manager's executive team as he looks to reboot performance after a string of disappointing earnings updates and big ticket ...
MarketWatch11h
AstraZeneca Expected to Post Higher Core Earnings, Revenue -- Earnings Preview
AstraZeneca is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS ...